For years, the GLP‑1 landscape has been defined by injectable biologics – potent and analytically demanding, but still relatively simple and very clean in terms of sample complexity. The FDA’s approval of an oral GLP‑1 fundamentally changes that equation. For drug developers, it signals a new era of formulation innovation. For chromatographers, it signals something else entirely: a dramatic expansion in analytical complexity, regulatory scrutiny, and the expectations placed on impurity testing.
As someone who has spent decades in the trenches of peptide analysis, I see the arrival of oral GLP‑1s as a structural turning point for the entire analytical ecosystem supporting these drugs.
A new playbook for GLP‑1s
The FDA’s approval of an oral GLP‑1 sends a clear message: the agency is ready to support alternative delivery routes – provided developers can prove they understand their molecules at a deeper level than ever before. Oral peptides demand more robust stability data, more aggressive impurity profiling, more comprehensive stress testing, and more evidence of control over degradation pathways. Timelines will tighten, expectations will rise, and analytical packages will grow thicker. The bar for demonstrating product understanding has officially moved.
Injectable GLP‑1s already require rigorous impurity testing, but oral formulations introduce entirely new stressors; gastrointestinal pH extremes, enzymatic degradation, excipient interactions, manufacturing stresses from tableting or encapsulation. Suddenly, the impurity landscape expands from “process‑related and storage‑related” to “process‑related, formulation‑related, GI‑related, and user‑environment‑related.” Companies must now anticipate what happens to the peptide not only in the warehouse, but in the stomach.
From an analytical standpoint, oral GLP‑1s trigger heightened regulatory expectations in several areas, such as more extensive forced‑degradation studies – for example: acidic, basic, oxidative, thermal, and enzymatic – regulators will expect all of it. This will lead to additional impurity identification where UV alone is no longer enough – MS, HRMS, and orthogonal chromatographic modes become essential. Complex formulations will translate to increased emphasis on excipient-API interactions. Regulators will want proof that the formulation itself isn’t generating new impurity pathways. In short: the analytical burden increases – exponentially.
What impurity testing looks like today
Current GLP‑1 impurity testing relies heavily on several analytical separation methods. Reversed‑phase HPLC/UHPLC has been used for separating closely related peptide variants, while ion‑exchange chromatography has been used for charge heterogeneity and size‑exclusion chromatography for aggregation. For identification and structural confirmation, LC-MS and HRMS have been the gold standard, and MALS has been used for higher‑order structure characterization.
These tools work well, but peptides are notoriously difficult analytes. They stick to surfaces, degrade unpredictably, and produce families of impurities that differ by a single amino acid or modification. Even with today’s best tools, chromatographers often feel like they’re chasing shadows.
And with more impurities, many at lower levels, detecting and quantifying trace degradants becomes essential. Oral formulations versus liquid injectables introduce more complex matrices and formulation excipients can interfere with separations and suppress MS signals. A single method can no longer capture the full impurity picture, thus there is a need for more orthogonality of methods.
Finally, while development timelines are shrinking, analytical complexity is growing – leading to an increase in the demand for faster and more robust methodologies. The result: traditional workflows begin to buckle under the weight of new expectations.
What “advanced” impurity testing really means
When people talk about “advanced impurity testing,” they’re not referring to a single technique – they’re referring to an integrated analytical strategy. This may include:
Multi‑dimensional chromatography (2D‑LC): RP × IEX or RP × SEC to resolve extremely similar impurities.
High‑resolution mass spectrometry: accurate‑mass identification of low‑level degradants.
Enhanced sample‑prep workflows designed to remove excipients and stabilize peptides.
Automated peak‑tracking and impurity mapping: essential for managing the sheer volume of data.
Real‑time stability analytics using rapid UHPLC methods to monitor degradation pathways continuously.
This is the future: deeper, faster, more connected analytical ecosystems.
Importantly, if impurity profiles are not fully understood or controlled, the consequences can be severe. Degradation can lower the active dose delivered orally, leading to reduced drug efficacy. Impurity aggregates or modified peptides can trigger immune responses leading to immunogenicity, reducing efficacy and sensitivity to the drug. Most regulatory agencies no longer accept unidentified peaks when it comes to impurity analyses, so this could cause regulatory delays or failures when taking the drug to market. In this case, manufacturing processes may need to be halted or redesigned, causing disruptions in the supply-chain. In the oral GLP‑1 era, analytical uncertainty becomes a business risk.
Interestingly, the rapid rise of GLP‑1 agonists echoes earlier waves in pharma – monoclonal antibodies in the 2000s, ADCs in the 2010s, and mRNA vaccines more recently. Each wave forced analytical labs to evolve quickly, adopt new technologies, and rethink old assumptions. GLP‑1s are now having their moment; and once again, chromatographers are being asked to lead the way.
Where GLP‑1 analysis is headed
Looking ahead, GLP-1 analysis is set to evolve along several key fronts. Greater automation and higher-throughput workflows will be essential as sample volumes continue to rise, while mass-spectrometry-driven characterization will play an increasingly central role – particularly for oral formulations and next-generation peptides. At the same time, more orthogonal chromatographic approaches will be needed to untangle ever more complex impurity profiles, alongside a growing emphasis on predictive stability modeling that uses analytical data to anticipate degradation pathways. Underpinning all of this will be closer collaboration between formulation scientists and analytical chemists, a necessity rather than a luxury when it comes to oral peptides.
The GLP-1 revolution is far from over – but as these molecules evolve, so too must the analytical strategies that support them.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
